Search Result

Results for "

inhibits cholesterol biosynthesis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	APC (2) Autophagy (3) c-Fms (1) Cytochrome P450 (2) Drug Metabolite (1) Endogenous Metabolite (8) Farnesyl Transferase (1) HMG-CoA Reductase (HMGCR) (3) Isotope-Labeled Compounds (1) LXR (1) γ-secretase (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Infection (4) Inflammation/Immunology (2) Metabolic Disease (13) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Acyltransferase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-104051

Monacolin J Antibiotic MB 530A; Lovastatin diol lactone	HMG-CoA Reductase (HMGCR) Autophagy	Metabolic Disease
Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of HMG-CoA reductase.

HY-122410

Dihydrolanosterol 1 Publications Verification	Cytochrome P450	Others
Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor. .

HY-N12846

Neokadsuranic acid A	Others	Metabolic Disease
Neokadsuranic acid A is a cholesterol biosynthesis inhibitor that reduces the activity of cholesterol. Neokadsuranic acid A is a triterpenoid compound that can be isolated from Kadsura heteroclita, a plant of the Schisandraceae family. Neokadsuranic acid A can be used to study the cholesterol biosynthesis pathway and its role in traditional medicine .

HY-N10232

Agistatin E	Others	Infection
Agistatin E is a pyranacetal originally isolated from a Fusarium sp. that inhibits the **cholesterol biosynthesis** .

HY-N10231

Agistatin D	Others	Infection Inflammation/Immunology
Agistatin D is a pyranacetal originally isolated from a Fusarium sp. that inhibits the **cholesterol biosynthesis** .

HY-125666

Agistatin B	Others	Infection
Agistatin B, isolated from fungus, is a mycotoxin. Agistatin B inhibits **cholesterol synthesis** .

HY-Y0889

1-(2,3-Dichlorphenyl)piperazine	Others	Metabolic Disease
1-(2,3-Dichlorphenyl)piperazine is a potent DHCR7 inhibitor with the activity of inhibiting cholesterol biosynthesis. 1-(2,3-Dichlorphenyl)piperazine is often used in biological research to evaluate the function of cholesterol biosynthesis pathway. The application of 1-(2,3-Dichlorphenyl)piperazine is of great significance for understanding diseases related to cholesterol biosynthesis .

HY-157528

CJ28	Endogenous Metabolite	Cancer
CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .

HY-122410S

Dihydrolanosterol-d7	Isotope-Labeled Compounds Cytochrome P450	Others
Dihydrolanosterol-d₇ is deuterium labeled Dihydrolanosterol. Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor[1].

HY-108040

NCX-6560	Others	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
NCX-6560 is an orally active nitric oxide releasing derivative of atorvastatin that inhibits cholesterol biosynthesis and has anti-inflammatory and antithrombotic activity .

HY-139576

Larsucosterol DUR-928	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576A

Larsucosterol sodium DUR-928 sodium	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-14925

Lapaquistat 1 Publications Verification T-91485	Endogenous Metabolite Drug Metabolite	Metabolic Disease
Lapaquistat (T-91485), a **cholesterol biosynthesis** inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-B1189S

Meglutol-d3 Dicrotalic acid-d₃; 3-Hydroxy-3-methylglutaric acid-d₃	Autophagy HMG-CoA Reductase (HMGCR) Endogenous Metabolite	Cardiovascular Disease
Meglutol-d₃ is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-139576B

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-16274

Lapaquistat acetate TAK-475	Others	Metabolic Disease
Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-116572

TASIN-1 hydrochloride	APC	Cancer
TASIN-1 hydrochloride is a selective inhibitor of truncated APC gene (adenomatous polyposis coli gene) and exerts cytotoxic effects through inhibition of cholesterol biosynthesis. TASIN-1 hydrochloride represents a potential strategy for prevention and intervention in CRC with mutant APC .

HY-116572A

TASIN-1	APC	Cancer
TASIN-1 is a selective inhibitor of truncated *APC* gene (adenomatous polyposis coli gene) and exerts cytotoxic effects through inhibition of cholesterol biosynthesis. TASIN-1 represents a potential therapeutic strategy for prevention and intervention in CRC with mutant APC .

HY-158050

PXB17	c-Fms	Cancer
PXB17 can inhibit CSF1R (IC₅₀ = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .

HY-107420

AY 9944 3 Publications Verification	Others	Metabolic Disease
AY 9944 is a specific **cholesterol biosynthesis** inhibitor. AY 9944 inhibits the 7-dehydro cholesterol Δ7-reductase (DHCR7) enzyme with an IC₅₀ of 13 nM. AY 9944 causes hypocholesterolemia and accumulation of 7DHC. At high doses, AY 9944 inhibits also in cultured embryos sterol Δ7-Δ8 isomerase, which causes the accumulation of cholest-8-en-3β-ol .

HY-113725

L 668411	Others	Others
L 668411 is a β-lactone inhibitor with activity against 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis. L 668411 inhibits rat liver cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase and [14C] acetate incorporation into sterols in cultured Hep G2 cells, and the inhibition appears to be irreversible in cells but reversible in cultured cells and animals.

HY-10016

E 2012 Maximum Cited Publications 7 Publications Verification	γ-secretase	Neurological Disease
E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .

HY-43515

ESI1	Endogenous Metabolite	Metabolic Disease
ESI1 is a small molecule epigenetic silencing inhibitor. ESI1 can trigger the formation of nuclear condensates of key lipid metabolism regulators SREBP1/2, concentrating transcriptional co-activators to drive lipid/cholesterol biosynthesis. ESI1 can promote myelin regeneration in demyelinated animal models and facilitate de novo myelination on regenerating CNS axons, reversing age-related declines in cognitive abilities .

HY-B2097

Incadronate disodium YM 175; Bisphonal	Farnesyl Transferase	Metabolic Disease
Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (K_i=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC₅₀=64 μM). Incadronate disodium has the potential for malignant tumors research .

HY-139090

3-Oxobetulin acetate 28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin	Others	Infection
3-Oxobetulin acetate is a derivative of the cholesterol biosynthesis inhibitor Betulin (HY-N0083). It inhibits the growth of P388 murine lymphocytic leukemia cells (EC₅₀=0.12 μg/mL), as well as human MCF-7 breast, SF-268 CNS, H460 lung, and KM20L2 colon cancer cells (GI₅₀s=8, 10.6, 5.2, and 12.7 μg/mL, respectively), but not BxPC-3 pancreas or DU145 prostate cancer cells (GI₅₀s=>10 μg/mL for both).2 3-Oxobetulin acetate inhibits replication of X4 tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC₅₀=13.4 μM). It is also active against L. donovani amastigotes when used at a concentration of 50 μM.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-122410

Dihydrolanosterol 1 Publications Verification	Triterpenes Structural Classification Microorganisms Classification of Application Fields Terpenoids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Cytochrome P450
Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor. .

HY-14925

Lapaquistat 1 Publications Verification T-91485	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Drug Metabolite
Lapaquistat (T-91485), a **cholesterol biosynthesis** inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-139576B

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	LXR Endogenous Metabolite
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-N12846

Neokadsuranic acid A	Triterpenes Structural Classification Kadsura heteroclita (Roxb.) Craib Terpenoids Source classification Plants Schisandraceae	Others
Neokadsuranic acid A is a cholesterol biosynthesis inhibitor that reduces the activity of cholesterol. Neokadsuranic acid A is a triterpenoid compound that can be isolated from Kadsura heteroclita, a plant of the Schisandraceae family. Neokadsuranic acid A can be used to study the cholesterol biosynthesis pathway and its role in traditional medicine .

HY-N10232

Agistatin E	Infection Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields	Others
Agistatin E is a pyranacetal originally isolated from a Fusarium sp. that inhibits the **cholesterol biosynthesis** .

HY-N10231

Agistatin D	Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Disease Research Fields Inflammation/Immunology	Others
Agistatin D is a pyranacetal originally isolated from a Fusarium sp. that inhibits the **cholesterol biosynthesis** .

HY-125666

Agistatin B	Infection Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields	Others
Agistatin B, isolated from fungus, is a mycotoxin. Agistatin B inhibits **cholesterol synthesis** .

HY-157528

CJ28	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
CJ28 is a cortisol biosynthesis inhibitor that significantly inhibits basal and stimulated cortisol production in human adrenal carcinoma cell lines. CJ28 exhibits inhibitory effects by reducing steroidogenesis and de novo cholesterol biosynthesis .

HY-139576

Larsucosterol DUR-928	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576A

Larsucosterol sodium DUR-928 sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	Cardiovascular Disease Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

Cat. No.	Product Name	Chemical Structure

HY-B1189S

Meglutol-d3
Meglutol-d₃ is the deuterium labeled Meglutol[1]. Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.

HY-122410S

Dihydrolanosterol-d7
Dihydrolanosterol-d₇ is deuterium labeled Dihydrolanosterol. Dihydrolanosterol is a subtrate of CYP51 and a cholesterol biosynthesis inhibitor[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

inhibits cholesterol biosynthesis

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products